AV-5124 is under clinical development by Viriom and currently in Phase I for Influenzavirus B Infections. According to GlobalData, Phase I drugs for Influenzavirus B Infections have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AV-5124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AV-5124 overview

AV-5124 is under development for the treatment and prevention of influenza A virus, H1N1 subtype infection, influenza B virus infections and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through oral route in the form of a tablet and acts by targeting cap-dependent endonuclease (CEN).

Viriom overview

Viriom (Viriom) operates as a clinical-stage drug development company that offers antivirals for HIV treatment and prevention. The company’s lead pipeline product includes Elpida, is a bioavailable prodrug. It also develops VM-1500A, a non-nucleoside HIV reverse transcriptase inhibitor. Viriom also provides development activities and early market access programs. The company serves hospital and over-the-counter market segments with drugs that provide treatment as well as pre-exposure and post-exposure prophylaxis. It operates in Japan and the US. Viriom is headquartered in San Diego, California, US.

For a complete picture of AV-5124’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.